Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

593
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
593
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

849
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
849
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

327
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
327
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

600
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
600
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

452
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
452

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hippocampal interictal discharges induce frontal spindles and enhance spindle-slow oscillation coupling in temporal lobe epilepsy.

Clinical neurophysiology practice·2026
Same author

Cerebellar hypoperfusion in anti-NF155 antibody-positive nodopathy: a retrospective case series using brain perfusion SPECT.

Frontiers in neurology·2026
Same author

Headache prevalence and types in multiple sclerosis and related neuroimmunological diseases: A multicenter study.

Cephalalgia : an international journal of headache·2026
Same author

A case of anti-nuclear matrix protein 2 antibody-positive dermatomyositis sine dermatitis with a challenging diagnosis due to the absence of typical skin manifestations.

Modern rheumatology case reports·2026
Same author

Diagnostic performance of central vein sign, paramagnetic rim lesion and cortical lesion in Asian patients with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Related Experiment Video

Updated: May 23, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.3K

[Sex-Based Differences and Shared Decision-Making in Myasthenia Gravis].

Noriko Isobe1

  • 1Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|March 10, 2025
PubMed
Summary

Myasthenia gravis affects females more often and is harder to treat in women. Personalized treatment choices considering sex-based differences are crucial for better outcomes.

More Related Videos

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

1.3K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.3K

Related Experiment Videos

Last Updated: May 23, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.3K
Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
05:44

Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice

Published on: October 13, 2023

1.3K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.3K

Area of Science:

  • Neurology
  • Immunology
  • Autoimmune Diseases

Background:

  • Myasthenia gravis is an autoimmune disorder affecting neuromuscular junctions.
  • Females exhibit higher prevalence and treatment resistance in myasthenia gravis.
  • Female patients often experience poorer quality of life post-treatment.

Purpose of the Study:

  • To highlight the importance of sex-based differences in myasthenia gravis management.
  • To emphasize the need for personalized treatment selection.
  • To inform shared decision-making with novel therapeutic options.

Main Methods:

  • Review of existing literature on myasthenia gravis prevalence and treatment outcomes.
  • Analysis of sex-based disparities in disease course and response to therapy.
  • Consideration of emerging treatment modalities and shared decision-making principles.

Main Results:

  • Female patients with myasthenia gravis show increased prevalence and reduced treatment efficacy.
  • Improving quality of life post-treatment is more challenging for female patients.
  • Novel treatments offer new avenues for tailored therapeutic strategies.

Conclusions:

  • Effective myasthenia gravis management requires acknowledging and addressing sex-based differences.
  • Personalized treatment plans, informed by patient-specific factors, are essential.
  • Shared decision-making is vital for optimizing care and improving patient outcomes, especially for females.